We were the first among all pharmaceutical companies in Russia to receive authorization to import a batch of an unregistered drug for patients undergoing bone marrow transplantation. The drug has been unavailable on the Russian market since 2020.
We collaborate with federal healthcare facilities across the country. We supply unregistered drugs to patients from the Central, Northwestern, Southern, Volga, Urals, Siberian, and North Caucasus federal districts.
We are among the top 50 suppliers of oncological drugs in Russia. We strictly follow the GDP standards by complying with the requirements for transportation and storage of preparations.
We invest in the development of an IT system for big data analytics in healthcare. We cooperate with scientific institutes and innovative Russian pharmaceutical manufacturers.
We support research and development organizations and implement our own health-tech solutions.